Navigation Links
Proteolix to Present Carfilzomib Clinical Data During the 2009 ASCO Annual Meeting
Date:5/15/2009

Therapeutics Location: Level 4, Valencia Room, W415A -- Phase II results of Study PX-171-007: A Phase Ib/II study of carfilzomib (CFZ), a selective proteasome inhibitor, in patients with selected advanced metastatic solid tumors. (Abstract #3515) Monday, June 1, 2009 at 3:45 p.m. ET Track: Developmental Therapeutics, Lymphoma and Plasma Cell Disorders Session: New Agents for Multiple Myeloma Location: Level 2, West Hall F1 -- Final results of PX-171-003-A0, part 1 of an open-label, single- arm, Phase II study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (MM). (Abstract #8504) Poster Presentations Monday, June 1, 2009 from 2:00 p.m. to 6:00 p.m. ET Track: Lymphoma and Plasma Cell Disorders Session: Lymphoma and Plasma Cell Disorders Location: Level 2, W240A -- PX-171-004, a multicenter Phase II study of carfilzomib (CFZ) in patients with relapsed myeloma: An efficacy update. (Abstract #8537) -- PX-171-006: Phase Ib multicenter dose escalation study of carfilzomib (CFZ) plus lenalidomide (LEN) and low-dose dexamethasone (loDex) in relapsed and refractory multiple myeloma (MM): Preliminary results. (Abstract #8541)

About Carfilzomib

Carfilzomib is the first in a new class of selective, irreversible proteasome inhibitors. Carfilzomib produces specific and sustained inhibition of the proteasome, leading to apoptosis in cancer cells with minimal off-target effects. In Phase 1 and Phase 2 clinical trials, carfilzomib has demonstrated single-agent activity in hematologic malignancies and solid tumors, including multiple myeloma, Waldenstrom's macroglobulinemia, mantle cell lymphoma, and renal cell carcinoma.

Proteolix is conducting a
'/>"/>

SOURCE Proteolix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Proteolix Announces New Appointment in Finance and Expands Clinical and Regulatory Leadership Team
2. Proteolix Announces Positive Data From Two Ongoing Phase 2 Clinical Trials of Carfilzomib in Multiple Myeloma at the 50th Annual Meeting of the American Society of Hematology
3. Proteolix Presents Preclinical Data for Oral Proteasome Inhibitor PR-047 at the 50th Annual Meeting of the American Society of Hematology
4. Proteolix Raises $79 Million in Series C Financing
5. Proteolixs Carfilzomib Receives Orphan Drug Designation for Treatment of Multiple Myeloma
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. China Biologic Products to Present at CCG IRs China Rising Conference and Oppenheimers China Dragon Call Conference in New York
8. EntreMed ENMD-2076 Phase 1 Data to Be Presented at ASCO Annual Meeting
9. Oncolytics Biotech(R) Inc.s Research Collaborators to Present Data on REOLYSIN(R) Clinical Trials at ASCO Conference
10. Trubion Announces Acceptance of Three Presentations on Its TRU-016 Product Candidate at the 2009 ASCO Annual Meeting
11. Bayer and Onyx Announce Nexavar Data Presentations at 45th American Society of Clinical Oncology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... , Sept. 2, 2014  TransCelerate BioPharma Inc. ... recommended approach for protecting personal data in Clinical ... patients and others. The document describes an approach ... from CSRs and other related clinical trial documents, ... The goal of the TransCelerate CSR Redaction approach ...
(Date:9/2/2014)... AVENTURA, Fla. , Sept. 2, 2014  Technology ... has announced that its wholly-owned subsidiary Renuell Int,l, Inc. ... National Aeronautics and Space Administration ("NASA") at the Johnson ... See photos: tapplic.com/houstonphotos/ ... stated, "We are very pleased to announce our latest, ...
(Date:9/2/2014)... Quincy, MA (PRWEB) September 02, 2014 ... announced today the signage of a distribution agreement ... Azelis is now distributing Myriant’s bio-succinic acid in ... Kingdom and Ireland, targeting customers in the industrial ... chemical distribution powerhouse, Azelis offers a far-reaching chemical ...
(Date:9/2/2014)... (PRWEB) September 02, 2014 Opertech ... new highly efficient, cost effective approach to sensory ... No. 8,820,265 by the U.S. Patent and Trademark ... Opertech. , “Opertech’s taste evaluation technology ... first automated high throughput system for rapid characterization ...
Breaking Biology Technology:TransCelerate BioPharma Inc. Releases Recommended Approach for Protecting Personal Data in Clinical Study Reports 2TransCelerate BioPharma Inc. Releases Recommended Approach for Protecting Personal Data in Clinical Study Reports 3Technology Applications International Corporation Subsidiary Enters Into Additional Exclusive Agreement with NASA at a Signing Ceremony at the Johnson Space Center In Houston, Texas 2Technology Applications International Corporation Subsidiary Enters Into Additional Exclusive Agreement with NASA at a Signing Ceremony at the Johnson Space Center In Houston, Texas 3Myriant and Azelis Sign European Distribution Agreement for Bio-Succinic Acid 2Opertech Bio Receives U.S. Patent for High-Throughput Taste Evaluation Technology 2
... , CAMBRIDGE, Mass., Aug. 11 Tolerx, ... therapies for immune-mediated diseases, today announced changes to the protocol for its ... of otelixizumab, a targeted T cell immunomodulator, in patients with new-onset autoimmune ... urable Response Therapy E valuation F or E arly ...
... WALTHAM, Mass., Aug. 11 Decision Resources, one of the world,s ... that the entry and uptake of premium-priced biologics will drive the ... $420 million in 2008 to nearly $2 billion in 2018. , ... Lupus Erythematosus finds that the primary drivers of market growth ...
... , , ... that BD Biosciences, a segment of BD (Becton, Dickinson and ... Pathway Navigation technologies into its new website. By leveraging ... its research customers to quickly and easily identify products and ...
Cached Biology Technology:Tolerx Announces Amendment to Phase 3 DEFEND Protocol 2Tolerx Announces Amendment to Phase 3 DEFEND Protocol 3Biologic Agents Will Drive the Systemic Lupus Erythematosus Drug Market to More Than Quadruple to Nearly $2 Billion in 2018 2Ingenuity's Technology Powers BD Cell Pathways Tool on New BD Biosciences Website 2
(Date:9/2/2014)... (September 2, 2014) In the battle between our ... unknown ally in bacteria-killing viruses known as phages. In ... Hospital, Partners In Health, Haiti,s National Public Health Laboratory, ... to give up their virulence in order to survive. ... found that cholera,s mutational escape from phage predation ...
(Date:9/2/2014)... also known as perching birds, that migrate by night ... in autumn to reach their destinations. This seasonal difference ... only make short migratory flights, says researcher Cecilia Nilsson ... Behavioral Ecology and Sociobiology . , Nilsson, in ... tracking radar to measure over three years the speed ...
(Date:9/2/2014)... What,s the price of your integrity? Tell the truth; everyone ... but at some point, we,ll lie if the benefit is ... brain in which we make that decision. , The ... Neuroscience . , "We prefer to be honest, even ... author and a postdoctoral associate at the Virginia Tech ...
Breaking Biology News(10 mins):War between bacteria and phages benefits humans 2War between bacteria and phages benefits humans 3Migrating birds sprint in spring, but take things easy in autumn 2Scientists find possible neurobiological basis for tradeoff between honesty, self-interest 2Scientists find possible neurobiological basis for tradeoff between honesty, self-interest 3Scientists find possible neurobiological basis for tradeoff between honesty, self-interest 4
... proteins are the bad guys that help bacterial pathogens do ... immune system. In essence, they knock down the front ... Now, researchers at the University of California, San Diego (UCSD) ... an effector protein called YpkA, one of several effectors of ...
... could soon be roaming our pastures, reports Cath O’Driscoll in ... in New Zealand have discovered that some cows have genes ... and plan to use this information to breed herds of ... plan to breed commercial herds producing milk with the unique ...
... H5N1 strain of avian influenza may hold the key to ... of researchers. In a study published today in the open ... antibodies taken from avian flu survivors in Vietnam can be ... virus in culture vitro and in mice. , The H5N1 ...
Cached Biology News:How plague-causing bacteria disarm host defense 2Skimmed milk -- Straight from the cow 2Avian influenza survivors' antibodies effective at neutralising H5N1 strain 2
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
... Quality ISO 9001:2000 Certified ... All Precedures Validated, SOP's Training ... Process for All Procedures GLP Documentation Upon ... one stop shopping point for all your ...
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Request Info...
Biology Products: